Muligheden for at patienten tager anden medicin der interagere med methotrexat (f. eks. medicin der påvirker methotrexat eliminering eller som binder sig til serumalbumin) bør altid overvejes, når der observeres unormale laboratoriefund eller når klinisk toksicitet observeres.
The possibility that the patient is taking other medications that interact with methotrexate (eg, medications which may interfere with methotrexate elimination or binding to serum albumin) should always be considered when laboratory abnormalities or clinical toxicities are observed.